Boston Scientific CRM update
This article was originally published in The Gray Sheet
Executive Summary
FDA is reviewing Boston Scientific's catch-up submissions covering manufacturing process modifications to its implantable defibrillators and cardiac resynchronization therapy defibrillators under the 30-day notice process, an FDA spokeswoman confirmed last week. The company pulled all of its ICD and CRT-D products off the market March 15 after it identified two manufacturing changes that were never submitted to the agency for pre-review, at the cost of about $5 million per day in lost sales, analysts estimate (1"The Gray Sheet" March 22, 2010). Boston Scientific sales reps have told electrophysiology practices to expect resolution within 30 days, with potential for approval for the changes in as little as eight business days. But FDA's Peper Long also confirmed a statement by a CDRH staffer in the March 26 Wall Street Journal that the agency is "not expediting" the firm's submissions at this point
You may also be interested in...
Boston Scientific Confirms Manufacturing Changes That Led To ICD Recall
Boston Scientific is working on a plan to prevent a repeat of its ongoing implantable defibrillator recall and providing additional details to physicians about the two manufacturing changes that prompted the move three weeks ago
Boston Scientific Recalls All Implantable Defibrillators, Suspends Sales
Boston Scientific is recalling all lines of its implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators nationwide because the firm made manufacturing process changes without proper FDA approval
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.